TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessment of function, nutrition and cognition, with attention to frailty, muscle loss and dehydration, and recommends pairing treatment with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications to older adults while accounting for age-related health needs. The paper applies the society’s Geriatrics 5Ms Framework to treatments including GLP-1 medications and calls for pretreatment assessment of function, nutrition and cognition.
Published in the Journal of the American Geriatrics Society, the paper was developed by the AGS Healthy Aging Special Interest Group. Its authors organize the guidance around clinical cases, using the 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to frame decisions about incretin therapies for older patients.
The report says clinicians should assess functional status, nutritional adequacy and cognitive impairment before treatment. It also highlights concerns relevant to older adults, including frailty and sarcopenia, the risk of losing lean muscle, malnutrition and dehydration. The framework does not treat prescribing as a medication-only decision: it recommends pairing therapy with resistance training and adequate dietary protein, in line with the importance of healthy habits alongside obesity medications.
For some patients, the authors say a team-based approach may be appropriate, involving professionals such as a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The report presents these as considerations for individualized care, not as a single plan that applies to every older adult.
Balancing Weight Treatment With Function
The framework addresses a gap between growing use of obesity medications and the evidence available for older patients. The report notes that older adults are underrepresented in clinical trials, leaving clinicians with less direct trial evidence for weighing potential benefits and risks in this age group.
That gap matters because treatment decisions may involve more than changes in weight or blood sugar. Muscle strength, mobility, hydration and nutrition can affect an older person’s ability to maintain independence and manage other conditions. By asking clinicians to consider these factors before prescribing and to plan supportive care alongside medication, the framework puts function and the patient’s priorities into the decision process.
The guidance may also help clinicians structure discussions with patients and care teams. It does not establish that a medication is appropriate for every older adult, nor does the source report provide results from a trial testing the framework. Its stated contribution is a practical approach to safer, patient-centered prescribing amid limited representation of older people in clinical studies.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Bowflex SelectTech 840 Adjustable Kettlebell
Fitbit Charge 6 Fitness Tracker – Porcelain/Silver
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The 5Ms framework offers a way to organize geriatric care around mental health and cognition, mobility, medications, complex health needs and what matters most to the patient. In this paper, the AGS group applies that structure to obesity medications that include GLP-1 therapies, which act through gut-derived hormonal pathways.
The source report says these medicines offer promising benefits for weight management, glycemic control and other health conditions. It does not provide specific estimates of benefit, compare individual drugs or set out a universal prescribing threshold. Instead, the paper focuses on how clinicians can adapt treatment decisions to the health, function and preferences of older adults.
The report is based on a framework paper, not a newly described clinical trial. It identifies age-related risks and care considerations, while the available source material does not report patient outcomes from applying the recommendations in practice.
Evidence and Patient Outcomes
The source material does not say whether the framework has been tested in clinical practice or whether its use changes medication safety, weight outcomes, mobility or quality of life. Those outcomes remain unreported in the provided account. It also does not specify how clinicians should weigh individual risks against expected benefits for particular patients or provide drug-by-drug recommendations.
The report identifies underrepresentation of older adults in clinical trials but gives no figures on the extent of that gap. The available summary also does not detail the framework’s full case examples, publication date beyond October 2026, or whether the AGS plans further guidance. Prescribing decisions therefore remain individualized, and the framework should not be read as evidence that every older adult will benefit from these medicines.
Clinical Use and Further Evidence
The paper is now available in the Journal of the American Geriatrics Society for clinicians to consult. The source does not announce a formal rollout, implementation study or scheduled update. In practice, the framework points clinicians toward assessing function, nutrition and cognition before treatment and considering supportive measures such as protein intake, resistance exercise and team-based care.
Further research would be needed to establish how well the approach works across different older patient groups and whether it improves outcomes or reduces harms. The report provides no timeline for such studies. For now, the main development is the publication of a structured clinical framework, with its effects in routine care still to be determined.
Key Questions
Who released the prescribing framework?
The American Geriatrics Society published it through work by its Healthy Aging Special Interest Group. The paper appeared in the Journal of the American Geriatrics Society.
Which medications does the framework address?
It discusses obesity medications, including GLP-1 medicines and other incretin therapies. The source summary does not give drug-by-drug prescribing instructions.
What should clinicians assess before prescribing?
The authors emphasize pretreatment review of functional status, nutritional adequacy and cognitive impairment, alongside age-related concerns such as frailty, muscle loss and dehydration.
Does the framework recommend care beyond medication?
Yes. It recommends pairing treatment with measures such as resistance training and adequate dietary protein. For some patients, the authors say a team including nutrition, physical therapy, fitness or behavioral health professionals may be suitable.
Has the framework been shown to improve patient outcomes?
The source report does not provide results from a trial of the framework or show that it improves outcomes. Its effects in clinical practice remain unclear.
Source: medicalxpress.com
